Dr. Karmali on Next Steps of Research Regarding Ibrutinib Maintenance in MCL

Video

Reem Karmali, MD, MS, assistant professor of medicine, Northwestern University Feinberg School of Medicine, discusses the next steps for research regarding the use of ibrutinib (Imbruvica) as maintenance therapy in mantle cell lymphoma (MCL).

Reem Karmali, MD, MS, assistant professor of medicine, Northwestern University Feinberg School of Medicine, discusses the next steps for research regarding the use of ibrutinib (Imbruvica) as maintenance therapy in mantle cell lymphoma (MCL).

A study that examined ibrutinib maintenance following intensive induction therapy showed that the approach is feasible and the toxicities are manageable, says Karmali. However, longer follow-up data are needed, as well as analysis of patients’ minimal residual disease (MRD) status. The primary objective of the study was to look at efficacy, which was assessed according to the rate of 3-year progression-free survival (PFS) rates.

However, an exploratory analysis looked at MRD status and an IgH polymerase chain reaction, based methodology. Investigators believe that MRD will provide better insight into whether patients can achieve deeper responses with ibrutinib maintenance. With this analysis, researchers hope to show a correlation between MRD status and PFS and overall survival that would warrant further exploration of ibrutinib maintenance, concludes Karmali.

Recent Videos
David Barrett, JD, the chief executive officer of ASGCT
Georg Schett, MD, vice president research and chair of internal medicine at the University of Erlangen – Nuremberg
David Barrett, JD, the chief executive officer of ASGCT
Bhagirathbhai R. Dholaria, MD, an associate professor of medicine in malignant hematology & stem cell transplantation at Vanderbilt University Medical Center
Caroline Diorio, MD, FRCPC, FAAP, an attending physician at the Cancer Center at Children's Hospital of Philadelphia
R. Nolan Townsend; Sandi See Tai, MD; Kim G. Johnson, MD
Daniela van Eickels, MD, PhD, MPH, the vice president and head of medical affairs for Bristol Myers Squibb’s Cell Therapy Organization
Paul Melmeyer, MPP, the executive vice president of public policy & advocacy at MDA
Daniela van Eickels, MD, PhD, MPH, the vice president and head of medical affairs for Bristol Myers Squibb’s Cell Therapy Organization
© 2024 MJH Life Sciences

All rights reserved.